What Does the Published Research Say About 5-Amino-1MQ?

What This Article Covers

This article summarizes published research on 5-Amino-1MQ for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

• Topic focus: 5‑Amino‑1‑methylquinolinium (5‑Amino‑1MQ) appears in the evidence set as a chemical entity linked to nicotinamide N‑methyltransferase (NNMT) inhibition via registry and patent search references [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
• Evidence composition: the evidence set aggregates human observational/biomarker studies related to NNMT, review literature on NNMT biology and translational interest, and preclinical reports on NNMT inhibition and structure–activity relationships (SAR) [pubmed:39067875; pubmed:37576910; pubmed:34029690; pubmed:33453420; pubmed:35756670; pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:37523719; pubmed:29320176; pubmed:36622754; pubmed:31589440].
• Scope note: the evidence set does not include human interventional trials of 5‑Amino‑1MQ or other NNMT inhibitors. Where human data are present, they are disease‑specific, observational, and focused on NNMT rather than on 5‑Amino‑1MQ per se.

Bottom Line

• The supplied literature does not report human clinical trials of 5‑Amino‑1MQ. Human data in this evidence set concern NNMT associations in specific diseases (urothelial bladder cancer; chronic kidney disease) and should not be generalized to therapeutic efficacy [pubmed:39067875; pubmed:37576910].
• Preclinical studies explore NNMT inhibition in animal and cell models, including cardiac, liver, kidney, and oncology‑related contexts, and detail NNMT inhibitor chemotypes and SAR; these findings are not established human outcomes [pubmed:40484359; pubmed:32389809; pubmed:41543936; pubmed:29320176; pubmed:31589440; pubmed:37523719; pubmed:36622754].
• The evidence set provides a chemical registry entry and patent‑search context for 5‑Amino‑1MQ but no human dosing, safety, or efficacy data [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

Human evidence (observational/associational; not interventional)

• Urothelial bladder cancer (UBC): NNMT in cancer‑associated fibroblasts is linked to tumor progression and resistance to immunotherapy, with mechanistic work connecting NNMT to macrophage modulation alongside analysis in human UBC cohorts [pubmed:39067875].
• Chronic kidney disease (CKD): NNMT is reported as a predictive marker of tubular fibrosis in CKD in human clinical context [pubmed:37576910].
• Interpretation boundaries: These studies inform NNMT’s disease associations and potential biomarker roles. They do not establish therapeutic benefit of NNMT inhibition or of 5‑Amino‑1MQ in humans [pubmed:39067875; pubmed:37576910].

Review context (mechanistic framing; not a substitute for outcomes)

• Reviews summarize NNMT’s catalytic role (methylation of nicotinamide to 1‑methyl‑nicotinamide), its intersections with cellular metabolism and epigenetic regulation, and its potential as a biomarker/target across diseases [pubmed:34029690; pubmed:33453420; pubmed:35756670]. Mechanistic plausibility does not establish clinical utility.

Preclinical evidence and chemical tools (non‑human)

• Liver/metabolism: ER stress–induced NNMT upregulation contributes to alcohol‑related fatty liver development in preclinical models [pubmed:32389809].
• Cardiac: NNMT inhibition improved cardiac structure and function in a heart‑failure‑with‑preserved‑ejection‑fraction (HFpEF) mouse model [pubmed:40484359].
• Kidney: NNMT inhibition counteracted tubular senescence and fibrosis in early‑stage CKD models (non‑human) [pubmed:41543936].
• Oncology/mechanisms: m6A RNA modification pathways regulating chemotherapy response via NNMT were demonstrated in preclinical systems [pubmed:36622754].
• Chemical probes/SAR: discovery and optimization of NNMT bisubstrate and high‑affinity inhibitors, including cell‑potent tools, define tractable scaffolds and structure–activity relationships [pubmed:29320176; pubmed:31589440; pubmed:37523719].
• Translation note: Animal/cell findings and chemical‑tool potency are not evidence of human clinical benefit or safety [pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:29320176; pubmed:31589440; pubmed:37523719; pubmed:36622754].

Chemical identity and patent context for 5‑Amino‑1MQ

• Chemical registry: 5‑Amino‑1‑methylquinolinium is indexed in PubChem [pubchem:950107].
• Intellectual property: A patent‑search record indicates filings and applications related to 5‑Amino‑1MQ as an NNMT inhibitor scaffold [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor]. These records do not substitute for peer‑reviewed human efficacy or safety data.

Limitations and open questions from this evidence set

• No human interventional data for 5‑Amino‑1MQ or any NNMT inhibitor are presented.
• Human findings are disease‑specific observational/biomarker associations (UBC; CKD) and should not be extrapolated to other conditions without new data [pubmed:39067875; pubmed:37576910].
• Dosing, safety, and generalized risk profiles in humans are not addressed by this evidence set.
• A substantial share of the evidence is preclinical, limiting translational certainty.

What Was Tested in Humans?

No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for 5-Amino-1MQ is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for 5-Amino-1MQ is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• [pubmed:39067875] NAD(+) metabolism enzyme NNMT in cancer‑associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. https://pubmed.ncbi.nlm.nih.gov/39067875/
• [pubmed:40484359] Nicotinamide‑N‑methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model. https://pubmed.ncbi.nlm.nih.gov/40484359/
• [pubmed:41543936] NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/41543936/
• [pubmed:34029690] Nicotinamide N‑methyl transferase (NNMT): An emerging therapeutic target. https://pubmed.ncbi.nlm.nih.gov/34029690/
• [pubmed:33453420] Nicotinamide N‑methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. https://pubmed.ncbi.nlm.nih.gov/33453420/
• [pubmed:37523719] Structure‑Activity Relationship Studies on Cell‑Potent Nicotinamide N‑Methyltransferase Bisubstrate Inhibitors. https://pubmed.ncbi.nlm.nih.gov/37523719/
• [pubmed:35756670] Nicotinamide N‑Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy. https://pubmed.ncbi.nlm.nih.gov/35756670/
• [pubmed:37576910] Nicotinamide N‑Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD. https://pubmed.ncbi.nlm.nih.gov/37576910/
• [pubmed:29320176] Discovery of Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/29320176/
• [pubmed:36622754] N6‑Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N‑methyltransferase. https://pubmed.ncbi.nlm.nih.gov/36622754/
• [pubmed:31589440] High‑Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/31589440/
• [pubchem:950107] PubChem compound record: 5‑Amino‑1‑methylquinolinium. https://pubchem.ncbi.nlm.nih.gov/compound/950107
• [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor] Google Patents search for 5‑Amino‑1MQ 5‑amino‑1‑methylquinolinium NNMT inhibitor. https://patents.google.com/?q=5-Amino-1MQ+5-amino-1-methylquinolinium+NNMT+inhibitor

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ